Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Trial Profile

Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Diffuse large B cell lymphoma; Lymphomatoid granulomatosis; Lymphoproliferative disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2017 Planned initiation date changed from 1 Dec 2017 to 11 Dec 2017.
    • 25 Nov 2017 Planned initiation date changed from 30 Nov 2017 to 1 Dec 2017.
    • 24 Nov 2017 Planned initiation date changed from 3 Nov 2017 to 30 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top